Maisam Amar

Risk factors for OXA-carbapenemase-producing Enterobacterales acquisition in Israel: A retrospective case control study

Maisam Amar, Ofra Barnett‐Griness, Regina Weber, Shereen Shehade et autres

il (code pays fourni par la source)

Secondary prophylaxis for Clostridioides difficile infection for patients on non-C. difficile antibiotics: a retrospective cohort study

Ronza Najjar‐Debbiny, Ofra Barnett‐Griness, Anat Arbel, Shai Cohen et autres

il (code pays fourni par la source)

Empyema Necessitans Following Bacille Calmette-Guérin Administration for Urothelial Carcinoma

Maisam Amar, Regina Weber, R M Yassin, Ola Salah et autres

Background Bacille Calmette-Guérin wash for urothelial carcinoma is a very common adjuvant treatment with a low potential for serious systemic adverse events. We present a case of a rare serious complication, empyema necessitans, following treatment with BCG. Case Presentation A 77-year-old patient …

il, us (code pays fourni par la source)

Effectiveness of Molnupiravir in High-Risk Patients: A Propensity Score Matched Analysis

Ronza Najjar‐Debbiny, Naomi Gronich, Regina Weber, Johad Khoury et autres

BACKGROUND: Molnupiravir was granted emergency use authorization for the treatment of mild to moderate coronavirus disease 2019 (COVID-19). In this study, we used population-based real-world data to evaluate the effectiveness of molnupiravir. METHODS: The database of the largest healthcare provider in Israel …

il, us (code pays fourni par la source)

Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients

Ronza Najjar‐Debbiny, Naomi Gronich, Regina Weber, Johad Khoury et autres

BACKGROUND: Paxlovid was granted an Emergency Use Authorization for the treatment of mild to moderate coronavirus disease 2019 (COVID-19), based on the interim analysis of the Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients (EPIC-HR) trial. Paxlovid effectiveness needs to be …

il, us (code pays fourni par la source)